

RESEARCH ARTICLE

Open Access



Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians

Margherita Piccardi^{1†}, Manuel Gentiluomo^{1†}, Stefania Bertoncini², Raffaele Pezzilli³, Bálint Erőss⁴, Stefania Bunduc^{4,5,6,7}, Faik G. Uzunoglu⁸, Renata Talar-Wojnarowska⁹, Tomas Vanagas¹⁰, Cosimo Sperti¹¹, Martin Oliverius¹², Mateus Nóbrega Aoki¹³, Stefano Ermini¹⁴, Tamás Hussein⁴, Ugo Boggi¹⁵, Krzysztof Jamrozak¹⁶, Evaristo Maiello¹⁷, Luca Morelli¹⁸, Ludmila Vodickova^{19,20,21}, Gregorio Di Franco¹⁸, Stefano Landi¹, Andrea Szentesi^{4,22,5}, Martin Lovecek²³, Marta Puzzone²⁴, Francesca Tavano²⁵, Hanneke W. M. van Laarhoven²⁶, Alessandro Zerbi^{27,28}, Beatrice Mohelnikova-Duchonova²⁹, Hannah Stocker^{30,31}, Eithne Costello³², Gabriele Capurso^{33,34}, Laura Ginocchi³⁵, Rita T. Lawlor³⁶, Giuseppe Vanella^{33,34}, Francesca Bazzocchi³⁷, Jakob R. Izbicki⁸, Anna Latiano²⁵, Bas Bueno-de-Mesquita³⁸, Ruggero Ponz de Leon Pisani³⁹, Ben Schöttker^{30,31}, Pavel Soucek²⁰, Péter Hegyi^{4,22,5,6}, Maria Gazouli⁴⁰, Thilo Hackert⁴¹, Juozas Kupcinskas⁴², Lina Poskiene⁴³, Matteo Tacelli³⁹, Susanne Roth⁴¹, Silvia Carrara⁴⁴, Francesco Perri²⁵, Viktor Hlavac²⁰, George E. Theodoropoulos⁴⁵, Olivier R. Busch⁴⁶, Andrea Mambriani³⁵, Casper H. J. van Eijck⁴⁷, Paolo Arcidiacono³⁹, Aldo Scarpa³⁶, Claudio Pasquali⁴⁸, Daniela Basso⁴⁹, Maurizio Lucchesi³⁵, Anna Caterina Milanetto⁴⁸, John P. Neoptolemos⁴¹, Giulia Martina Cavestro²⁴, Dainius Janciauskas⁴³, Xuechen Chen^{30,50}, Roger Chammass^{51,52}, Mara Goetz⁸, Hermann Brenner^{30,53,54}, Livia Archibugi^{33,34}, Michael Dannemann⁵⁵, Federico Canzian⁵⁶, Sergio Tofanelli² and Daniele Campa^{1*}

Abstract

Background The genomes of present-day non-Africans are composed of 1–3% of Neandertal-derived DNA as a consequence of admixture events between Neandertals and anatomically modern humans about 50–60 thousand years ago. Neandertal-introgressed single nucleotide polymorphisms (aSNPs) have been associated with modern human disease-related traits, which are risk factors for pancreatic ductal adenocarcinoma (PDAC), such as obesity, type 2 diabetes, and inflammation. In this study, we aimed at investigating the role of aSNPs in PDAC in three Eurasian populations.

Results The high-coverage Vindija Neandertal genome was used to select aSNPs in non-African populations from 1000 Genomes project phase 3 data. Then, the association between aSNPs and PDAC risk was tested independently in Europeans and East Asians, using existing GWAS data on more than 200 000 individuals. We did not find

[†]Margherita Piccardi and Manuel Gentiluomo these authors share the first position.

*Correspondence:

Daniele Campa

daniele.campa@unipi.it

Full list of author information is available at the end of the article



any significant associations between aSNPs and PDAC in samples of European descent, whereas, in East Asians, we observed that the Chr10p12.1-rs117585753-T allele (MAF = 10%) increased the risk to develop PDAC (OR = 1.35, 95%CI 1.19–1.54, $P = 3.59 \times 10^{-6}$), with a P-value close to a threshold that takes into account multiple testing.

Conclusions Our results show only a minimal contribution of Neandertal SNPs to PDAC risk.

Keywords Neandertal, Pancreatic cancer, Association study, Introgression, Eurasians, Admixture

Introduction

By comparing the genome sequences of Neandertal and modern genomes it has been shown that ~1–3% of the genomes of present-day non-Africans are of Neandertal ancestry [1–3] with 8–20% higher levels of Neandertal ancestry in East Asians compared to Europeans [4–6]. Through phenotypic information from genome-wide association studies it has been shown that introgressed Neandertal DNA still significantly influences the phenotypic variability of anatomically modern humans (AMHs) today. Neandertal-introgressed Single Nucleotide Polymorphisms (aSNPs) have for example been associated with several human traits, such as the genetic susceptibility of type 2 diabetes (T2D), obesity, age of menopause, neurological traits, morning preference, skin and hair morphology, immune response, and inflammation [7–17]. Among these traits are several factors, such as overweight, obesity, T2D, deregulation of the immune system, and chronic inflammation that play a key role in pancreatic ductal adenocarcinoma (PDAC) onset and progression [18–21].

Alongside a small number of environmental risk factors [22–24], PDAC susceptibility has a strong genetic component. Rare high penetrance variants involved in hereditary syndromes (reviewed in Gentiluomo et al.) and frequent low and moderate penetrance variants, discovered through candidate gene and genome-wide association studies (GWAS), have been identified as playing a role in PDAC onset [25–39]. However, the common risk loci discovered so far explain only a small proportion of the overall heritability of the disease [40]. Furthermore, PDAC is a late onset disease [29, 41, 42], thus loci associated with PDAC susceptibility tend to persist in the AMH gene pool, eluding purifying selection.

Considering that aSNPs are associated with several PDAC risk factors and that the genetic contribution to PDAC etiology still needs to be elucidated, we aimed at investigating the Neandertal legacy of PDAC genetic risk. We analysed PDAC GWAS cohorts from different Eurasian populations for significant associations with aSNPs to study the role of Neandertal admixture and PDAC risk in different ancestry groups. This study is the first attempt to investigate the role of archaic admixture on PDAC development.

Results

In this study, 389 144 aSNPs were identified among the non-African populations of the 1000 Genomes project [43]. The association between aSNPs and the risk of developing PDAC was tested in three ancestry groups: non-Finnish Europeans, Finns, and East Asians.

For non-Finnish Europeans, 161 283 aSNPs were available to be analysed in the discovery phase, using the genotypes of PanScan + PanC4 studies. Considering a $P < 0.05$, 263 aSNPs resulted associated with PDAC risk in the combined PanScan + PanC4 dataset. All 263 of these aSNPs also passed the $P < 0.05$ threshold when only PanScan or PanC4 were considered separately. Among them, 212 showed residual LD ($r^2 > 0.5$). After pruning, 51 independent aSNPs associations spanning across 51 loci were observed (Fig. 1, Additional File 1). None of the 51 aSNPs remained associated with PDAC after correction for multiple testing ($p_j = 2.30 \times 10^{-6}$). The SNP with the lowest P-value was Chr2p14-rs12998719, (OR = 1.11, 95%CI 1.05–1.16, $P = 5.51 \times 10^{-5}$) (Table 1). This variant has been already reported to be associated with PDAC risk [32] and was genotyped in the context of the PANDORA consortium (replication phase). The results of the replication phase did not show a statistically significant association (OR = 1.46, 95%CI 0.95–1.15, $P = 0.38$) (Table 1).

In FinnGen, 251 090 aSNPs were found, and after LD-pruning ($r^2 > 0.5$), 1154 independent aSNPs with a $P < 0.05$ were observed (Fig. 1). The aSNP with the lowest P-value in FinnGen was Chr3p24.3-rs113955626 (OR = 1.35, 95%CI 1.17–1.55, $P = 4.79 \times 10^{-5}$) (Table 1); this aSNP did not reach the Bonferroni adjusted significance threshold ($p_j = 2.30 \times 10^{-6}$).

In the JaPAN dataset, which includes data of the meta-analysis of three GWAS conducted on individuals of Asian descent, 158 393 aSNPs were analysed. The association analysis showed 656 independent aSNPs with a $P < 0.05$ in all the three GWASs (Fig. 1). The best candidate was Chr10p12.1-rs117585753 (OR = 1.35, 95%CI 1.19–1.54, $P = 3.59 \times 10^{-6}$), whose P-value was very close to the Bonferroni-adjusted threshold ($p_j = 2.28 \times 10^{-6}$) (Table 1).




Fig. 1 aSNPs filtering and analysis workflow for each ancestry group. The figure displays aSNPs analysis workflow for non-Finnish Europeans, Finns, and East Asians. The 389 144 aSNPs identified in all non-African populations from 1000 Genomes project phase 3, were filtered and analysed for each ancestry group. aSNP Neandertal introgressed SNP. ¹aSNPs that showed an association P-value < 0.05 in PanScan, PanC4 and in the two datasets combined. aSNPs with a P < 0.05 in PanScan (7850), PanC4 (8141), and the combined datasets (8718). ²aSNPs with a P-value < 0.05 and an identical direction of the effect in all the three GWASs included in JaPAN

Discussion

We tested the effects of Neandertal introgression on PDAC susceptibility in three ancestry groups. In non-Finnish Europeans and Finns, no novel significant associations between aSNPs and PDAC were observed.

In JaPAN, we found that the T allele of Chr10p12.1-rs117585753 increased the risk to develop PDAC (P=3.59×10⁻⁶). This association was not statistically significant when considering multiple testing. However, it is very close to the Bonferroni corrected threshold (p_j=2.28×10⁻⁶). The functional implications of this aSNP have not been clarified yet: according to GWAS catalog, it is not associated with any complex human trait.

Interestingly, the T allele of Chr10p12.1-rs117585753 is present in EAS (MAF=10%), whereas it is almost absent in the other populations represented in 1000 Genomes project (e.g., MAF<0.01 in Europeans from 1000 Genomes project). Since Chr10p12.1-rs117585753 is polymorphic only in Asians, it is possible that the role of this aSNP in complex traits has not been elucidated yet because most of the association studies have been conducted in cohorts with participants of European descent [46]. The lower number of studies with Asian individuals implies that the associations between SNPs, which are

rare in Europeans but common in Asians, still need further investigation to be understood entirely.

Chr10p12.1-rs117585753 lies in an intron of the protein-coding *PRTFDC1* gene, in which, according to the GWAS catalog, there are SNPs associated with blood cell count [47–49]. Several white and red blood cell count parameters have been used to predict immune response and inflammation in various diseases, including PDAC [50, 51]. One SNP in *PRTFDC1* (Chr10p12.1-rs7905553) is in weak LD (r²=0.14, D’=0.96) with Chr10p12.1-rs117585753 in EAS, and according to GWAS catalog it is associated with red blood cell distribution width (RDW) [52], which is a parameter of erythrocyte variation. RDW has been proposed as a biomarker of the inflammatory state that could predict progression/prognosis in PDAC [53], suggesting a potential contribution of the *PRTFDC1* genomic region and Chr10p12.1-rs117585753 in PDAC and immunity.

Several Neandertal-derived haplotypes involved in immunity have been reported to be under selection after Neandertal-AMH introgression. In fact, the positive selection of aSNPs that lead to adaptation (adaptive introgression) has been observed to be driven by the immune response to pathogens [8, 9, 54–57].

Possible limitations of our approach are represented by the fact that we could have underestimated the role

Table 1 Candidate aSNPs for each ancestry group

Panel A. Association studies results							
Population	aSNP	Position (GRCh37)	Alleles (M/m)	Gene ^a	MAF ^b	OR (95% C.I.)	P
PanS-can + PanC4 ^c	rs12998719	2:67583252	G/A	–	29%	1.11 (1.05–1.16)	5.51 × 10 ⁻⁵
PANDoRA ^c	rs12998719	2:67583252	G/A	–	28%	1.05 (0.95–1.15)	0.38
FinnGen	rs113955626	3:23107748	C/T	–	7%	1.35 (1.17–1.55)	4.79 × 10 ⁻⁵
JaPAN	rs117585753	10:25190572	C/T	<i>PRTFDC1</i>	10%	1.35 (1.19–1.54)	3.59 × 10 ⁻⁶

Panel B. Top SNP population-based frequency											
Population	aSNP	Position (GRCh37)	Alleles (M/m)	1000G MAF			gnomAD MAF			HGDP ^d	
				EUR	FIN	EAS (%)	EUR (%)	FIN	EAS (%)	EUR (%)	EAS
PanScan + PanC4 ^c	rs12998719	2:67583252	G/A	27%	30%	43	36	29%	42	25	35%
FinnGen	rs113955626	3:23107748	C/T	4%	4%	13	5	8%	14	8	18%
JaPAN	rs117585753	10:25190572	C/T	8% ₀₀	5% ₀₀	10	1	3% ₀₀	9	1	8%

Panel A shows the summary statistics of aSNPs with the lowest association P-value, panel B shows the minor allele frequency of SNPs with the lowest P-value of associations across several datasets

aSNP Neandertal introgressed SNP; M major allele; m, minor allele; MAF minor allele frequency; OR Odds Ratio; 95% C.I. 95% Confidence Interval; *PRTFDC1* phosphoribosyl transferase domain containing 1; 1000G 1000 Genomes project phase 3 [43]; gnomAD Genome Aggregation Database [44]; HGDP Human Genome Diversity Project [45] EUR Europeans; FIN Finns; EAS East Asians

^a Gene in which aSNP lies

^b MAF of the SNP of interest in the analysed datasets. Since allele frequencies are not freely available in JaPAN dataset, the MAF in East Asians from 1000G is reported

^c PanScan + PanC4 (discovery phase), PANDoRA (replication phase)

^d In HGDP, SNP frequency in Finns is not available. Frequency in all European populations is displayed

of rare variants (MAF < 1%) because we did not have enough statistical power to detect associations between rare aSNPs and PDAC, although we used the largest PDAC datasets currently available, which included more than 200 000 individuals of three different ancestries. An additional potential limitation of this work is that 93 695 out of 389 144 aSNPs identified in Eurasian genomes could not be found in PanScan + PanC4, FinnGen, and JaPAN. Therefore, the role of these aSNPs in PDAC susceptibility was not explored. In future analyses, larger reference panels for imputation could be used to maximize the investigated Neandertal-derived genetic variability.

Conclusions

In conclusion, we observed that the Neandertal introgressed DNA does not influence PDAC susceptibility in populations of European descent. Interestingly, we observed a potential association between Chr10p12.1-rs117585753-T and an increased risk of developing PDAC in populations of Asian descent, although not formally significant after correction for multiple testing. This aSNP is polymorphic only in East

Asians and is situated in a genomic region involved in immunity. Further investigations are needed to elucidate the evolutionary processes that lead to these aSNPs in the AMH gene pool and the role of aSNPs in PDAC risk, and more broadly, to explore the Neandertal legacy in the susceptibility to other cancer types.

Methods

Neandertal SNPs identification

The method to select aSNPs was previously described [12]. Briefly, to define a potential introgressed allele, we used four criteria that needed to be fulfilled: (a) the allele is shared between the Vindija Neandertal [5] and at least one non-African population from 1000 Genomes project phase 3 [43]; (b) the allele is not present in Yoruba from sub-Saharan Africa; (c) the allele is carried in homozygous state by Vindija Neandertal; (d) based on the haplotype length, the allele is more likely derived from Neandertal-AMH admixture than incomplete lineage sorting (ILS). To apply the fourth criterion, an approach, that was previously described by Huerta-Sánchez et al., and Dannemann et al. was used [54, 58]. Briefly, it allows the identification of putative Neandertal introgressed regions in all non-African 1000 Genomes project

populations. Two recombination maps [59, 60] were used to calculate the expected ILS segments length based on the local recombination rate. Then, the probability that a segment length was consistent with ILS was computed and the resulting P-values were corrected through Benjamini–Hochberg method. Haplotypes that showed an adjusted P-value < 0.05 were considered as introgressed from Neandertal. The aSNPs used in the following analyses lay on one of these Neandertal-derived haplotypes.

All the analyses were based on human genome assembly GRCh37, and only biallelic loci were considered, excluding indels.

Study populations

The association between aSNPs and PDAC risk was tested in three ancestry groups: non-Finnish Europeans, Finns and East Asians. A two-phase association study (discovery and replication) was performed to examine if aSNPs identified in non-Finnish Europeans affected PDAC susceptibility. On the other hand, a validation set was not available for Finns and East Asians, and the association between aSNPs and PDAC was tested by searching for aSNPs in FinnGen and JaPAN datasets, respectively (see below).

For non-Finnish European analyses, the discovery set included data of the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case–Control Consortium (PanC4). The data were downloaded from the database of Genotypes and Phenotypes (dbGaP, <https://www.ncbi.nlm.nih.gov/gap/>). The dbGaP study accession numbers were: phs000206.v5.p3 and phs000648.v1.p1.; the project reference number was #12644. Details about data collection, genotyping methods and analyses are described in the original publications [26, 31, 32, 61].

Genotype data were imputed separately, for each dataset, using the Michigan Imputation Server (<https://imputationserver.sph.umich.edu>) [62] and the Haplotype Reference Consortium (HRC, V.r1.1) as reference panel [63]. Prior to the imputation, the following quality controls were applied: genotypes missingness (call rate < 0.9), heterozygosity (> 3 SD from the mean), relatedness (PI_HAT > 0.2), PCA outliers (using PCA), and Hardy–Weinberg equilibrium ($P < 1 \times 10^{-6}$). After imputation, SNPs with low imputation quality (INFO score $r^2 < 0.7$) were excluded. Finally, the imputed datasets were merged. A total of 7 543 430 SNPs passed the quality controls on the autosomal genome, and 8738 PDAC cases and 7034 controls were used in the analysis (Table 2).

The replication of aSNPs with a P-value of association with PDAC risk lower than the Bonferroni-adjusted threshold (see below) was attempted in the Pancreatic Disease Research (PANDoRA) consortium [64, 65]. PANDoRA is a multicentric study on pancreatic cancer based mainly on European countries (Greece, Italy, Germany, Netherlands, Denmark, Czech Republic, Hungary, Poland, Ukraine, Lithuania, UK). In addition, PANDoRA includes a subgroup of Brazilian cases and controls that were excluded from the validation set in this study because PanScan + PanC4 (discovery set) included only Caucasian samples, while Brazilians belong to different ancestries (unlike the other PANDoRA samples). Information on sex, and age (recruitment for controls and diagnosis for the cases) was collected for each participant. The controls were enrolled among the general population, blood donors or hospitalised individuals not affected by cancer, chronic pancreatitis, or diabetes [64]. For this study, 4983 individuals (1894 PDAC cases and 3089 controls) from PANDoRA were included in the analysis (Table 2).

Table 2 Study population description for each ancestry group

Population	Cases	Controls	Sex		Median age (25–75% percentile)		Total number of subjects
			Male	Female	Cases	Controls	
<i>non-Finnish Europeans</i>							
PanScan + PanC4 ^a	8738	7034	54%	46%	65 (55–75)	65 (55–75)	15 772
PANDoRA ^a	1894	3089	51%	49%	67 (59–73)	59 (49–67)	4983
<i>Finns</i>							
FinnGen	1249	259 583	–	–	–	–	260 832
<i>East Asians</i>							
JaPAN ^b	2039	32 592	49.3–62.6%	–	62.7–66.3	43.6–56.3	34 631

The table shows the number of cases and controls in PanScan + PanC4, PANDoRA, FinnGen and JaPAN. Male and female count and median age of cases and controls are displayed for each study

^a PanScan + PanC4 (discovery phase), PANDoRA (replication phase)

^b Data for male count and age are displayed as minimum–maximum values of the three GWASs included in JaPAN

Data not available: “–”




Fig. 2 Manhattan and Quantile–Quantile (Q–Q) plots of PanScan + PanC4 association study results. The P-values displayed in Manhattan (A) and Q–Q plots (B) are calculated combining PanScan and PanC4 datasets. The plots were done using *qqman* R package (<https://cran.r-project.org/web/packages/qqman/index.html>) [68]. The inflation factors (λ) did not indicate systematic inflation for PanScan ($\lambda = 1.02$), PanC4 ($\lambda = 1.05$), and combined datasets ($\lambda = 1.05$). The inflation factors were computed using *simtrait* R package (<https://cran.r-project.org/web/packages/simtrait/index.html>) [69]

Non-Finnish Europeans and Finns were analysed separately because PanScan + PanC4 and PANDoRA mainly include subjects with Central European ancestry. We used the FinnGen Release 8 (R8) data that consists of GWAS summary statistics of 1249 pancreatic cancer cases and 259 583 controls with Finnish ancestry (Table 2). Subjects affected by other cancer types were excluded from the controls (<https://FinnGen.gitbook.io/documentation/>) [66].

To examine the association between aSNPs identified in East Asians and PDAC, we downloaded JaPAN consortium dataset that consisted of summary statistics of a meta-analysis of three GWASs (JaPAN, National Cancer Center and BioBank Japan GWASs). Comprehensive information on genotyping and data analysis are given in the original publication [67]. Summary statistics for the GWAS analysis are available on the JaPAN consortium website (http://www.aichi-med-u.ac.jp/JaPAN/current_initiatives-e.html) and include 34 631 individuals of East Asian origin (2039 PDAC cases and 32 592 controls) (Table 2).

Data and statistical analyses

For non-Finnish Europeans, the association between aSNPs and PDAC susceptibility was tested in the PanScan + PanC4 dataset using logistic regression analysis, adjusting for age, sex and the top eight principal components (Fig. 2). To obtain a list of independent aSNPs, all aSNPs in linkage disequilibrium (LD; $r^2 > 0.5$) with each other were excluded, and in each LD block the aSNP with the lowest association P-value was selected. Then, all aSNPs showing an association lower than the threshold for statistical significance corrected for multiple testing

in PanScan, PanC4 and in the combined datasets were selected for replication in PANDoRA.

The genomic DNA of the PANDoRA samples was extracted from circulating blood using the Qlamp[®] 96 DNA Qcube[®] HT Kit (Qiagen, Hilden, Germany). The genotyping was done using TaqMan RealTime PCR assays in 384-well plates. Each plate included cases and controls, duplicated samples for quality controls (QCs) and negative controls. The fluorescent signal detection was detected through a QuantStudio[™] 5 Real-Time PCR system (ThermoFisher, USA) and genotypes were called using the QuantStudio[™] Design and Analysis Software v1.5.1. Samples with a genotyping call rate lower than 75% were excluded from the analysis. Hardy–Weinberg equilibrium test was performed with the Pearson chi-square test. To test the association between aSNPs and PDAC risk in PANDoRA, a logistic regression adjusted for age, sex, and country of origin was used.

For Finns and East Asians, the analyses were carried out in parallel, keeping separated the two ancestry groups. Considering that for FinnGen and JaPAN we used summary statistics, we looked at the P-value for association in these two datasets for the aSNPs selected for the two populations. Since JaPAN is a meta-analysis of three studies, along with P-value, the concordance of the direction of the effect between the three GWASs was considered.

P-value correction for multiple testing was performed using Bonferroni correction and considering the independent ($r^2 < 0.8$) aSNPs. The adjusted significance thresholds were: $0.05/19\ 623 = 2.55 \times 10^{-6}$ for PanScan + PanC4 and PANDoRA; $0.05/21\ 780 = 2.30 \times 10^{-6}$ for FinnGen; $0.05/21\ 965 = 2.28 \times 10^{-6}$ for JaPAN.

Abbreviations

95% C.I.	95% Confidence interval
AMH	Anatomically modern human
aSNP	Neandertal introgressed single nucleotide polymorphism
dbGaP	Database of genotypes and phenotypes
EAS	East Asians from 1000 genomes project phase 3
EUR	Europeans from 1000 genomes project phase 3
gnomAD	Genome aggregation database
GWAS	Genome-wide association study
HGDP	Human genome diversity project
HRC	Haplotype Reference Consortium
ILS	Incomplete lineage sorting
JaPAN	Japan Pancreatic Cancer Research consortium
LD	Linkage disequilibrium
MAF	Minor allele frequency
OR	Odds ratio
PanC4	Pancreatic Cancer Case Control consortium
PANDoRA	Pancreatic Disease Research consortium
PanScan	Pancreatic Cancer Cohort consortium
PCA	Principal component analysis
PDAC	Pancreatic ductal adenocarcinoma
QC	Quality controls
Q-Q plot	Quantile–quantile plot
RDW	Red blood cell distribution width
T2D	Type 2 diabetes

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40659-023-00457-y>.

Additional file 1: Title of data: Independent associations ($P < 0.05$) identified in PanScan+PanC4 association studies. Description of data: Independent ($r^2 < 0.5$) aSNPs showing an association $P < 0.05$ in PanScan, PanC4, and combined datasets. The displayed summary statistics and MAF are referred to the analyses with the combined datasets. (Abbreviations: aSNP, Neandertal introgressed Single Nucleotide Polymorphism; m, minor allele; M, major allele, MAF, minor allele frequency).

Acknowledgements

This article is based upon work from COST Action “Identification of biological markers for prevention and translational medicine in pancreatic cancer (TRANSPAN)”, CA21116, supported by COST (European Cooperation in Science and Technology). This research used genotyping data provided to the PANDoRA consortium by the EPIC cohort, for which we would like to thank the contributors from EPIC UK. We want to acknowledge the participants and investigators of the FinnGen study.

Author contributions

The study was designed by DC, MD and ST; the experiments and statistical analyses were carried out by MP (Margherita Piccardi), MG (Manuel Gentiluomo), and SB (Stefania Bertoini). The manuscript was drafted by MP (Margherita Piccardi), MG (Manuel Gentiluomo), MD, FC, ST and DC. The other authors collected the samples, provided the data and contributed in the analysis of the results. All authors critically read, and approved the manuscript.

Funding

This study was supported by Associazione Italiana Ricerca Cancro (AIRC IG n. 26343) [Aldo Scarpa], Italian Ministry of Health (FIMPCUP_J38D19000690001) [Aldo Scarpa], the Ministry of Health of the Czech Republic (Grant number NV19-08-00113) [Pavel Soucek], Cancer Research UK (C7690/A26881) [Eithne Costello], Pancreatic Cancer UK Research Innovation Fund [Eithne Costello], Charles University Research Fund (Cooperatio No. 43 -Surgical Disciplines) [Ludmila Vodickova], Ministry of Health of the Czech Republic (AZV NU21-07-00247) [Ludmila Vodickova], Ministry of Health of the Czech Republic (grant no. NV19-03-00097 to B.M-D.) [Beatrice Mohelniková Duchoňová], Italian Ministry of Health grants to Fondazione “Casa Sollievo della Sofferenza” IRCCS Hospital, San Giovanni Rotondo (FG), Italy [Francesco Perri], and by the “5 × 1000” voluntary contribution [Francesco Perri].

Availability of data and materials

The PanScan and PanC4 genotyping data are available from the dbGaP website (study accession numbers phs000206.v5.p3 and phs000648.v1.p1). The JaPAN data used in this work are available in the JaPAN consortium website (http://www.aichi-med-u.ac.jp/JaPAN/current_initiatives-e.html). FinnGen R8 dataset of PDAC cases and controls (“C3_PANCREAS_EXALLC”) is downloadable from the FinnGen official website (<https://finngen.gitbook.io/documentation/>). The PANDoRA data for this work will be made available to researchers who submit a reasonable request to the corresponding author, conditional to approval by the PANDoRA Steering Committee and Ethics Commission of the Medical Faculty of the University of Heidelberg. Data will be stripped from all information allowing identification of study participants.

Declarations

Ethics approval and consent to participate

Individual-level genotyping data were used in this work for PanScan, PanC4 and PANDoRA. Each study participating in PanScan and PanC4 obtained approval from the responsible institutional review board (IRB) and IRB certification permitting data sharing in accordance with the NIH Policy for sharing of Data Obtained in NIH-Supported or NIH-Conducted Genome Wide Association Studies. The PANDoRA study protocol was approved by the Ethics Commission of the Medical Faculty of the University of Heidelberg. In accordance with the Declaration of Helsinki, written informed consent was obtained from each participant. FinnGen and JaPAN (meta-analysis of JaPAN consortium, BioBank Japan and National Cancer Center GWASs) summary statistics were used in this study. FinnGen has the permission to use samples from Finnish biobanks and data from national health registers for research. Each sample is coded and individual data will not be released. The project was evaluated by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District. FinnGen adhere to the Biobank Law, the Personal Data Act and EU Data Protection Regulation. JaPAN consortium GWAS study protocol was approved by the Ethical Review Board of Aichi Medical University, the Institutional Ethics Committee of Aichi Cancer Center, the Human Genome and Gene Analysis Research Ethics Committee of Nagoya University, and the ethics committees of the participating hospitals. BioBank Japan GWAS protocol was accepted by the ethics committees of the RIKEN Center for Integrative Medical Sciences. The informed consent for each participant was collected following the corresponding institutional ethics committee guidelines. National Cancer Center GWAS project was approved by the ethics committee of the National Cancer Center.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Biology, Unit of Genetics, University of Pisa, Via Derna 1, 56126 Pisa, Italy. ²Department of Biology, Unit of Zoology and Anthropology, University of Pisa, Pisa, Italy. ³Potenza County Medical Association, Potenza, Italy. ⁴Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary. ⁵Center for Translational Medicine, Semmelweis University, Budapest, Hungary. ⁶Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary. ⁷Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ⁸Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ⁹Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland. ¹⁰Department of Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania. ¹¹Department DISCOG, Chirurgia Generale 1, University of Padova, Padua, Italy. ¹²Department of Surgery, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic. ¹³Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Curitiba, Brazil. ¹⁴Blood Transfusion Service, Azienda Ospedaliero-Universitaria Meyer, Children’s Hospital, Florence, Italy. ¹⁵Division of General and Transplantation Surgery, University of Pisa, Pisa, Italy. ¹⁶Department of Hematology, Transplantation and Internal Medicine, University of Warsaw, Warsaw, Poland. ¹⁷Department of Oncology, Fondazione IRCCS “Casa Sollievo Della Sofferenza” Hospital, San Giovanni Rotondo,

Foggia, Italy. ¹⁸Department of Translational Research and New Technologies in Medicine and Surgery, General Surgery Unit, University of Pisa, Pisa, Italy. ¹⁹Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. ²⁰Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. ²¹Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic. ²²János Szentágothai Research Center, University of Pécs, Pécs, Hungary. ²³Department of Surgery I, University Hospital Olomouc, Olomouc, Czech Republic. ²⁴Gastroenterology and Gastrointestinal Endoscopy Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy. ²⁵Division of Gastroenterology and Research Laboratory, Fondazione IRCCS "Casa Sollievo Della Sofferenza" Hospital, San Giovanni Rotondo, Foggia, Italy. ²⁶Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands. ²⁷Pancreatic Unit, IRCCS Humanitas Research Hospital, Milan, Italy. ²⁸Department of Biomedical Sciences, Humanitas University, Milan, Italy. ²⁹Department of Oncology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. ³⁰Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. ³¹Network Aging Research (NAR), Heidelberg University, Heidelberg, Germany. ³²Department of Molecular & Clinical Cancer Medicine, University of Liverpool, Liverpool, UK. ³³Digestive and Liver Disease Unit, S Andrea Hospital, Rome, Italy. ³⁴Pancreas Translational and Clinical Research Center, Pancreato-Biliary Endoscopy and Endoscopic Ultrasound, San Raffaele Scientific Institute IRCCS, Milan, Italy. ³⁵Oncological Department, Oncology of Massa Carrara, ASL Toscana Nord Ovest, Massa Carrara, Italy. ³⁶ARC-NET Research Centre and Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy. ³⁷Department of Surgery, Fondazione IRCCS "Casa Sollievo Della Sofferenza" Hospital, San Giovanni Rotondo, Foggia, Italy. ³⁸Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. ³⁹Pancreato-Biliary Endoscopy and Endoscopic Ultrasound, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute IRCCS, Milan, Italy. ⁴⁰Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. ⁴¹Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany. ⁴²Department of Gastroenterology and Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania. ⁴³Department of Pathology, Lithuanian University of Health Sciences, Kaunas, Lithuania. ⁴⁴Department of Gastroenterology, Endoscopic Unit, IRCCS Humanitas Research Hospital, Milan, Italy. ⁴⁵First Department of Propaedeutic Surgery, Hippocration General Hospital, National and Kapodistrian University of Athens, Athens, Greece. ⁴⁶Department of Surgery, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands. ⁴⁷Department of Surgery, Erasmus MC University Medical Center, Rotterdam, the Netherlands. ⁴⁸Department DISCOG, Chirurgia Generale 3, University of Padova, Padua, Italy. ⁴⁹Department DIMED, Laboratory Medicine, University of Padova, Padua, Italy. ⁵⁰Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany. ⁵¹Department of Radiology and Oncology, Institute of Cancer of São Paulo (ICESP) São Paulo, Sao Paulo, Brazil. ⁵²Faculty of Medicine, University of São Paulo, São Paulo, Brazil. ⁵³Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany. ⁵⁴German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. ⁵⁵Estonian Biocentre, Institute of Genomics, University of Tartu, Tartu, Estonia. ⁵⁶Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Received: 30 June 2022 Accepted: 20 July 2023

Published online: 13 August 2023

References

- Green RE, Krause J, Briggs AW, Maricic T, Stenzel U, Kircher M, et al. A draft sequence of the neanderthal genome. *Science*. 2010;328(5979):710–22.
- Fu Q, Li H, Moorjani P, Jay F, Slepchenko SM, Bondarev AA, et al. Genome sequence of a 45,000-year-old modern human from western Siberia. *Nature*. 2014;514(7523):445–9.
- Prüfer K, Racimo F, Patterson N, Jay F, Sankararaman S, Sawyer S, et al. The complete genome sequence of a Neanderthal from the Altai mountains. *Nature*. 2014;505(7481):43–9.
- Wall JD, Yang MA, Jay F, Kim SK, Durand EY, Stevison LS, et al. Higher levels of neanderthal ancestry in East Asians than in Europeans. *Genetics*. 2013;194(1):199–209.
- Prüfer K, de Filippo C, Grote S, Mafessoni F, Korlević P, Hajdinjak M, et al. A high-coverage Neanderthal genome from Vindija cave in Croatia. *Science*. 2017;358(6363):655–8.
- Chen L, Wolf AB, Fu W, Li L, Akey JM. Identifying and interpreting apparent neanderthal ancestry in African individuals. *Cell*. 2020;180(4):677–687.e16.
- Sankararaman S, Mallick S, Dannemann M, Prüfer K, Kelso J, Pääbo S, et al. The genomic landscape of Neanderthal ancestry in present-day humans. *Nature*. 2014;507(7492):354–7.
- Deschamps M, Laval G, Fagny M, Itan Y, Abel L, Casanova JL, et al. Genomic signatures of selective pressures and introgression from archaic hominins at human innate immunity genes. *Am J Hum Genet*. 2016;98(1):5–21.
- Sams AJ, Dumaine A, Nédélec Y, Yotova V, Alfieri C, Tanner JE, et al. Adaptively introgressed Neanderthal haplotype at the OAS locus functionally impacts innate immune responses in humans. *Genome Biol*. 2016;17(1):246.
- Simonti CN, Vernot B, Bastarache L, Bottinger E, Carrell DS, Chisholm RL, et al. The phenotypic legacy of admixture between modern humans and Neanderthals. *Science*. 2016;351(6274):737–41.
- McCoy RC, Wakefield J, Akey JM. Impacts of Neanderthal-introgressed sequences on the landscape of human gene expression. *Cell*. 2017;168(5):916–927.e12.
- Dannemann M. The population-specific impact of Neanderthal introgression on human disease. *Genome Biol Evol*. 2021. <https://doi.org/10.1093/gbe/evaa250>.
- McArthur E, Rinker DC, Capra JA. Quantifying the contribution of Neanderthal introgression to the heritability of complex traits. *Nat Commun*. 2021;12(1):4481.
- Reilly PF, Tjahjadi A, Miller SL, Akey JM, Tucci S. The contribution of Neanderthal introgression to modern human traits. *Curr Biol*. 2022;32(18):R970–83.
- McArthur E, Rinker DC, Capra JA. Quantifying the contribution of Neanderthal introgression to the heritability of complex traits. *Nat Commun*. 2021;12(1):4481.
- Wei X, Robles CR, Pazokitoroudi A, Ganna A, Gusev A, Durvasula A, et al. The lingering effects of Neanderthal introgression on human complex traits. *eLife*. 2023;12:e80757.
- Dannemann M, Kelso J. The contribution of Neanderthals to phenotypic variation in modern humans. *Am J Hum Genet*. 2017;101(4):578–89.
- Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. *Cancer Discov*. 2016;6(8):852–69.
- Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. *Diabetes*. 2017;66(5):1103–10.
- Eibl G, Cruz-Monserrate Z, Korc M, Petrov MS, Goodarzi MO, Fisher WE, et al. Diabetes mellitus and obesity as risk factors for pancreatic cancer. *J Acad Nutr Diet*. 2018;18(4):555–67.
- Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. *Int J Mol Sci*. 2019;20(3):676.
- Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. *Int J Epidemiol*. 2015;44(1):186–98.
- Barone E, Corrado A, Gemignani F, Landi S. Environmental risk factors for pancreatic cancer: an update. *Arch Toxicol*. 2016;90(11):2617–42.
- Lu Y, Gentiluomo M, Lorenzo-Bermejo J, Morelli L, Obazee O, Campa D, et al. Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. *J Med Genet*. 2020;57(12):820–8.
- Low SK, Kuchiba A, Zembutsu H, Saito A, Takahashi A, Kubo M, et al. Genome-wide association study of pancreatic cancer in Japanese population. *PLoS ONE*. 2010;5(7):e11824.
- Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. *Nat Genet*. 2010;42(3):224–8.
- Campa D, Rizzato C, Stolzenberg-Solomon R, Pacetti P, Vodicka P, Cleary SP, et al. The TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. *Int J Cancer J Int Cancer*. 2015;137(9):2175–83.

28. Campa D, Pastore M, Gentiluomo M, Talar-Wojnarowska R, Kupcinskas J, Malecka-Panas E, et al. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. *Oncotarget*. 2016;7(35):57011–20.
29. Campa D, Gentiluomo M, Obazee O, Ballerini A, Vodickova L, Hegyi P, et al. Genome-wide association study identifies an early onset pancreatic cancer risk locus. *Int J Cancer*. 2020;147(8):2065–74.
30. Rizzato C, Campa D, Pezzilli R, Soucek P, Greenhalf W, Capurso G, et al. ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic disease ReseArch (PANDoRA) consortium. *Oncol Rep*. 2013;29(4):1637–44.
31. Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, et al. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nat Genet*. 2014;46(9):994–1000.
32. Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, et al. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nat Genet*. 2015;47(8):911–6.
33. Amundadottir LT. Pancreatic cancer genetics. *Int J Biol Sci*. 2016;12(3):314–25.
34. Gentiluomo M, Peduzzi G, Lu Y, Campa D, Canzian F. Genetic polymorphisms in inflammatory genes and pancreatic cancer risk: a two-phase study on more than 14 000 individuals. *Mutagenesis*. 2019. <https://doi.org/10.1093/mutage/gez040>.
35. Lin Y, Nakatochi M, Hosono Y, Ito H, Kamatani Y, Inoko A, et al. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. *Nat Commun*. 2020. <https://doi.org/10.1038/s41467-020-16711-w>.
36. Corradi C, Gentiluomo M, Gajdán L, Cavestro GM, Kreivenaite E, Franco GD, et al. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. *Int J Cancer*. 2021. <https://doi.org/10.1002/ijc.33475>.
37. Galeotti AA, Gentiluomo M, Rizzato C, Obazee O, Neoptolemos JP, Pasquali C, et al. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. *J Med Genet*. 2021;58(6):369–77.
38. Pistoni L, Gentiluomo M, Lu Y, López de Maturana E, Hlavac V, Vanella G, et al. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. *Carcinogenesis*. 2021;42(8):1037–45.
39. Corradi C, Lencioni G, Gentiluomo M, Felici A, Latiano A, Kiudelis G, et al. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. *J Med Genet*. 2023. <https://doi.org/10.1136/jmg-2022-108910>.
40. Chen F, Childs EJ, Mocci E, Bracci P, Gallinger S, Li D, et al. Analysis of heritability and genetic architecture of pancreatic cancer: a PanC4 study. *Cancer Epidemiol Prev Biomark*. 2019;28(7):1238–45.
41. Matsuda Y. Age-related morphological changes in the pancreas and their association with pancreatic carcinogenesis. *Pathol Int*. 2019;69(8):450–62.
42. Nodari Y, Gentiluomo M, Mohelnikova-Duchonova B, Kreivenaite E, Milanetto AC, Skieceviciene J, et al. Genetic and non-genetic risk factors for early-onset pancreatic cancer. *Dig Liver Dis*. 2023. <https://doi.org/10.1016/j.dld.2023.02.023>.
43. The 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature*. 2015;526(7571):68–74.
44. Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genome-wide mutational constraint map quantified from variation in 76,156 human genomes. *bioRxiv*. 2022. <https://doi.org/10.1101/2022.03.20.485034v2>.
45. Bergström A, McCarthy SA, Hui R, Almarri MA, Ayub Q, Danecek P, et al. Insights into human genetic variation and population history from 929 diverse genomes. *Science*. 2020;367(6484):eaay5012.
46. Mills MC, Rahal C. A scientometric review of genome-wide association studies. *Commun Biol*. 2019;2(1):1–11.
47. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The polygenic and monogenic basis of blood traits and diseases. *Cell*. 2020;182(5):1214–1231.e11.
48. Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. *Cell*. 2020;182(5):1198–1213.e14.
49. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. *Cell*. 2016;167(5):1415–1429.e19.
50. Feng L, Gu S, Wang P, Chen H, Chen Z, Meng Z, et al. White blood cell and granulocyte counts are independent predictive factors for prognosis of advanced pancreatic cancer. *Gastroenterol Res Pract*. 2018;8(2018):8096234.
51. Montagnana M, Danese E. Red cell distribution width and cancer. *Ann Transl Med*. 2016;4(20):399.
52. Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. Leveraging polygenic functional enrichment to improve GWAS power. *Am J Hum Genet*. 2019;104(1):65–75.
53. Dang C, Wang M, Qin T, Qin R. Clinical importance of preoperative red-cell volume distribution width as a prognostic marker in patients undergoing radical surgery for pancreatic cancer. *Surg Today*. 2021. <https://doi.org/10.1007/s00595-021-02374-7>.
54. Dannemann M, Andrés AM, Kelso J. Introgression of neandertal- and denisovan-like haplotypes contributes to adaptive variation in human toll-like receptors. *Am J Hum Genet*. 2016;98(1):22–33.
55. Quach H, Rotival M, Pothlichet J, Loh YHE, Dannemann M, Zidane N, et al. Genetic adaptation and Neandertal admixture shaped the immune system of human populations. *Cell*. 2016;167(3):643–656.e17.
56. Nédélec Y, Sanz J, Baharian G, Szpiech ZA, Pacis A, Dumaine A, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. *Cell*. 2016;167(3):657–669.e21.
57. Jagoda E, Xue JR, Reilly SK, Dannemann M, Racimo F, Huerta-Sanchez E, et al. Detection of Neandertal adaptively introgressed genetic variants that modulate reporter gene expression in human immune cells. *Mol Biol Evol*. 2022;39(1):304.
58. Huerta-Sánchez E, Jin X, Asan BZ, Peter BM, Vinckenbosch N, et al. Altitude adaptation in Tibetans caused by introgression of denisovan-like DNA. *Nature*. 2014;512(7513):194–7.
59. Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, et al. A high-resolution recombination map of the human genome. *Nat Genet*. 2002;31(3):241–7.
60. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, et al. Integrating common and rare genetic variation in diverse human populations. *Nature*. 2010;467(7311):52–8.
61. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nat Genet*. 2009;41(9):986–90.
62. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype imputation service and methods. *Nat Genet*. 2016;48(10):1284–7.
63. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48(10):1279–83.
64. Campa D, Rizzato C, Capurso G, Giese N, Funel N, Greenhalf W, et al. Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic disease ReseArch (PANDoRA) consortium. *Dig Liver Dis*. 2013;45(2):95–9.
65. Campa D, Gentiluomo M, Stein A, Aoki MN, Oliverius M, Vodičková L, et al. The PANcreatic Disease ReseArch (PANDoRA) consortium: ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. *Crit Rev Oncol Hematol*. 2023;1(186): 104020.
66. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature*. 2023;613(7944):508–18.
67. Lin Y, Nakatochi M, Hosono Y, Ito H, Kamatani Y, Inoko A, et al. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. *Nat Commun*. 2020;11(1):3175.
68. Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. *J Open Source Softw*. 2018;3(25):731.
69. Yao Y, Ochoa A. Limitations of principal components in quantitative genetic association models for human studies. *bioRxiv*. 2023. <https://doi.org/10.1101/2022.03.25.485885v2>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.